<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
85043-075-05
</NDCCode>
<PackageDescription>
1 SYRINGE in 1 CARTON (85043-075-05) / .25 mL in 1 SYRINGE
</PackageDescription>
<NDC11Code>
85043-0075-05
</NDC11Code>
<ProductNDC>
85043-075
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Vabrinty
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Leuprolide Acetate
</NonProprietaryName>
<DosageFormName>
INJECTION, SUSPENSION, EXTENDED RELEASE
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20251215
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA AUTHORIZED GENERIC
</MarketingCategoryName>
<ApplicationNumber>
NDA021343
</ApplicationNumber>
<LabelerName>
URONOVA PHARMACEUTICALS, INC.
</LabelerName>
<SubstanceName>
LEUPROLIDE ACETATE
</SubstanceName>
<StrengthNumber>
7.5
</StrengthNumber>
<StrengthUnit>
mg/.25mL
</StrengthUnit>
<Pharm_Classes>
Gonadotropin Releasing Hormone Receptor Agonist [EPC], Gonadotropin Releasing Hormone Receptor Agonists [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-12-18
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20251215
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>